S 18326

Drug Profile

S 18326

Latest Information Update: 03 Nov 2003

Price : $50

At a glance

  • Originator Servier
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 03 Nov 2003 No development reported - Phase-I for Thrombosis in France (PO)
  • 05 Apr 2000 A preclinical study has been added to the pharmacokinetics section
  • 19 May 1998 A study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top